NCT03977090View on ClinicalTrials.gov

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Geptanolimab Injection

GB226 3mg/kg, q2w, iv.

DRUG

Fruquintinib

Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off

Trial Locations (1)

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

Sponsors
All Listed Sponsors
collaborator

Hutchison Medipharma Limited

INDUSTRY

lead

Genor Biopharma Co., Ltd.

INDUSTRY